We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+17.25%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.31B
AUM Growth
-$35.5M
Cap. Flow
-$36M
Cap. Flow %
-2.75%
Top 10 Hldgs %
77.05%
Holding
40
New
3
Increased
8
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$25.2M
2
WGS icon
GeneDx Holdings
WGS
+$7.39M
3
RLAY icon
Relay Therapeutics
RLAY
+$7M
4
KYTX icon
Kyverna Therapeutics
KYTX
+$6.49M
5
IPSC icon
Century Therapeutics
IPSC
+$6.27M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$45.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$17.1M
4
ABCL icon
AbCellera Biologics
ABCL
+$10.7M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLFS icon
1
BioLife Solutions
BLFS
$1.56B
$187M 14.25%
8,707,165
– –
RVMD icon
2
Revolution Medicines
RVMD
$38.8B
$171M 13.06%
4,406,875
-1,210,724
-22% -$45.3M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.63B
$170M 12.95%
1,073,500
+4,500
+0.4% +$578K
LAB icon
4
Standard BioTools
LAB
$343M
$113M 8.64%
63,959,677
+2,052,072
+3% +$5.02M
WGS icon
5
GeneDx Holdings
WGS
$1.98B
$92.2M 7.04%
3,526,411
+390,000
+12% +$7.39M
RNAM
6
DELISTED
Avidity Biosciences
RNAM
$85.2M 6.5%
2,084,841
– –
RLAY icon
7
Relay Therapeutics
RLAY
$4.04B
$55.1M 4.21%
8,448,574
+1,025,000
+14% +$7M
ILMN icon
8
Illumina
ILMN
$30.2B
$50.1M 3.83%
480,000
+225,056
+88% +$25.2M
NTLA icon
9
Intellia Therapeutics
NTLA
$1.5B
$44.8M 3.42%
2,000,000
+125,000
+7% +$2.98M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29.1B
$41.3M 3.15%
170,000
-188,000
-53% -$29.7M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
$35.2M 2.69%
326,378
– –
DNLI icon
12
Denali Therapeutics
DNLI
$3.67B
$30.2M 2.3%
1,300,000
– –
GPCR icon
13
Structure Therapeutics
GPCR
$3.39B
$27.5M 2.1%
700,000
-416,867
-37% -$17.1M
EXAS
14
DELISTED
Exact Sciences
EXAS
$27.5M 2.1%
650,000
– –
TNYA icon
15
Tenaya Therapeutics
TNYA
$162M
$20.9M 1.59%
6,732,971
– –
NGNE icon
16
Neurogene
NGNE
$657M
$19.1M 1.46%
524,616
– –
VCYT icon
17
Veracyte
VCYT
$3.59B
$18.6M 1.42%
857,904
– –
FDMT icon
18
4D Molecular Therapeutics
FDMT
$524M
$16.8M 1.28%
800,000
– –
BEAM icon
19
Beam Therapeutics
BEAM
$2.66B
$15.8M 1.21%
675,000
– –
VERV
20
DELISTED
Verve Therapeutics
VERV
$14.9M 1.14%
3,059,094
– –
IPSC icon
21
Century Therapeutics
IPSC
$355M
$13.2M 1.01%
5,190,506
+1,984,126
+62% +$6.27M
PLRX icon
22
Pliant Therapeutics
PLRX
$64.4M
$10.8M 0.82%
1,000,000
– –
TNGX icon
23
Tango Therapeutics
TNGX
$4.43B
$10.2M 0.78%
1,188,349
– –
TSVT
24
DELISTED
2seventy bio
TSVT
$7.7M 0.59%
2,000,000
– –
CDXS icon
25
Codexis
CDXS
$158M
$6.2M 0.47%
2,000,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Casdin Capital held 40 positions worth $1.31B, down 2.6% from $1.35B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Casdin Capital's Q2 2024 filing shows 3 new, 8 increased, 5 reduced and 2 closed positions. Its largest new stake was Contineum Therapeutics: 296,666 shares worth $5.22M. The largest sale was Revolution Medicines, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Casdin Capital's largest Q2 2024 buy was Contineum Therapeutics: 296,666 shares worth $5.22M.
  • Casdin Capital added most to Illumina in Q2 2024, an estimated $25.2M increase.
  • Casdin Capital's biggest Q2 2024 reduction was Revolution Medicines, cutting an estimated $45.3M.
  • Casdin Capital fully exited AbCellera Biologics in Q2 2024, selling an estimated $10.7M.
  • Casdin Capital's ten largest holdings make up 77% of its $1.31B portfolio in Q2 2024.
  • Casdin Capital opened 3 new positions and closed 2 in Q2 2024.
  • Casdin Capital's portfolio value fell 2.6% quarter-over-quarter to $1.31B.

Based on Casdin Capital's 13F filing for Q2 2024, filed 14 Aug 2024.